Filing Flows › 60 Degrees Pharmaceuticals (SXTP) › Q1 2025
60 Degrees Pharmaceuticals (SXTP) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
60 Degrees Pharmaceuticals (SXTP) reported revenue of $164K for the first quarter 2025 (Q1 2025), +55% from a year earlier and -32% from the quarter before.
60 Degrees Pharmaceuticals, Q1 2025: revenue $164K (+55% year over year), net loss $1.9M, operating cash flow −$1.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $164K | -32% | +55% |
| Operating profit | −$1.9M | — | — |
| Net earnings | −$1.9M | — | — |
| Operating cash flow | −$1.6M | — | — |
What changed
Revenue was $164K in Q1 2025, up 55% year over year and down 32% from the previous quarter.
Gross margin was 55.2%, up 17.1 points from a year earlier. Operating costs exceeded revenue by $1.9M, an operating margin of -1168.4%. Operating expenses grew 45% against revenue growth of 55%. The quarter ended with a net loss of $1.9M, narrower than the previous quarter's $2.0M loss. Minority interests bore $1K of it: to shareholders the quarter was a loss of $1.9M.
Operating cash flow was −$1.6M. Non-cash charges added back $17K of depreciation and amortization and $187K of share-based compensation. Capital expenditures of $3K exceeded it, leaving free cash flow of −$1.6M.
Questions
What was 60 Degrees Pharmaceuticals' revenue in the first quarter 2025?
60 Degrees Pharmaceuticals (SXTP) reported revenue of $164K for the first quarter 2025 (Q1 2025), +55% from a year earlier and -32% from the quarter before.